Get the Stockscreener App
2.53
7.20%
0.17
Inmune Bio Inc stock is traded at $2.53, with a volume of 4.70M.
It is up +7.20% in the last 24 hours and down -65.20% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$2.36
Open:
$2.31
24h Volume:
4.70M
Relative Volume:
13.15
Market Cap:
$182.90M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-1.515
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
-59.71%
1M Performance:
-65.20%
6M Performance:
-52.22%
1Y Performance:
-68.34%
1-Day Range:
$2.295
$2.769
1-Week Range:
$1.89
$11.64
52-Week Range:
$1.89
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
2.53 | 182.90M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
INMB’s Stock Market Adventure: 47.11% YTD Growth Amidst Volatility - investchronicle.com
Balance Sheet Dive: INmune Bio Inc (INMB)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Bank of America Corp DE Boosts Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity - Seeking Alpha
INmune Bio, Inc. (NASDAQ:INMB) Shares Bought by Two Sigma Investments LP - Defense World
(INMB) On The My Stocks Page - news.stocktradersdaily.com
INmune Bio Collaborates on TBI and Alzheimer’s Study - TipRanks
INmune Bio, Inc. Collaborates on Study Showing XPro™ Treatment Reduces Alzheimer’s-like Pathology After Traumatic Brain Injury in Mice - Nasdaq
XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer's Disease: Supported by Department of Defense - The Manila Times
Xpro(TM) Reduces Amyloid And Enhances Behavior Post - MarketScreener
Breakthrough: New Drug Reduces Alzheimer's Risk After Brain Injury, DoD-Backed Study Shows - Stock Titan
Two Sigma Advisers LP Takes Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
Lucid Capital Markets initiates Buy rating for INmune Bio stock - Investing.com India
Lucid Capital Markets initiates Buy rating for INmune Bio stock By Investing.com - Investing.com Nigeria
INMB Stock Set for Growth with Positive Analyst Coverage | INMB Stock News - GuruFocus
Millennium Management LLC Boosts Stake in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
Are You MINDFuL Of INmune Bio's Upcoming Alzheimer's Trial Readout? - RTTNews
Northern Trust Corp Acquires 9,154 Shares of INmune Bio, Inc. (NASDAQ:INMB) - Defense World
BNP Paribas Financial Markets Has $119,000 Stock Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
When (INMB) Moves Investors should Listen - news.stocktradersdaily.com
Where are the Opportunities in (INMB) - news.stocktradersdaily.com
Dimensional Fund Advisors LP Acquires 10,491 Shares of INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio: XPro Trial Readout In Alzheimer’s Disease Offers Big Opportunity (NASDAQ:INMB) - Seeking Alpha
Wells Fargo & Company MN Buys 2,155 Shares of INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio to Attend RBC Healthcare Conference - TipRanks
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference - The Manila Times
INmune Bio Sets Stage for Key Biotech Insights at RBC Healthcare Conference Next Week - Stock Titan
Raymond James raises INmune Bio stock target to $23 - MSN
Barclays PLC Increases Stake in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - MSN
INmune Bio, Inc. (NASDAQ:INMB) Q1 2025 Earnings Call Transcript - Insider Monkey
INmune Bio’s Earnings Call: Promise and Challenges - TipRanks
Mariner LLC Acquires New Holdings in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update - The Manila Times
Earnings call transcript: INmune Bio Q1 2025 shows narrowed losses, stock rises - Investing.com
INmune Bio Reports Q1 2025 Results and Updates - TipRanks
INMUNE BIO Earnings Results: $INMB Reports Quarterly Earnings - Nasdaq
(INMB) Trading Signals - news.stocktradersdaily.com
INmune Bio appoints new accounting firm By Investing.com - Investing.com Nigeria
INmune Bio appoints new accounting firm - Investing.com
INmune Bio Inc (INMB) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
JPMorgan Chase & Co. Has $53,000 Stock Holdings in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th - The Manila Times
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on ... - Eagle-Tribune
Renaissance Technologies LLC Increases Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
LPL Financial LLC Boosts Stock Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Receives $22.80 Average PT from Analysts - Defense World
INmune Bio (INMB) Expected to Announce Quarterly Earnings on Thursday - Defense World
Geode Capital Management LLC Has $1.70 Million Stock Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
A stock that deserves closer examination: INmune Bio Inc (INMB) - uspostnews.com
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inmune Bio Inc Stock (INMB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tesi Raymond Joseph | President and CEO |
Sep 12 '24 |
Buy |
6.38 |
15,380 |
98,048 |
1,554,106 |
| Moss David J | Chief Financial Officer |
Sep 12 '24 |
Buy |
6.38 |
7,690 |
49,024 |
1,275,869 |
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):